Congressional Biosimilar Pathway Sponsors Use Letter-Writing Campaign To End Exclusivity Confusion
Executive Summary
Seven congressional sponsors of the legislation that established FDA's biosimilars approval pathway are weighing in with the agency about how it should implement it.
You may also be interested in...
Biosimilars Exclusivity Tug-of-War Brewing In The Mail; Can A Letter Add Eight Years To Reviews?
Rising concerns among generic firms about how FDA will interpret biosimilar exclusivity provisions may have escalated due to fears about the consequences of increased congressional scrutiny of the new pathway.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.